MannKind Corporation (MNKD)Healthcare | Biotechnology | Danbury, United States | NasdaqGM
3.95 USD
-0.11
(-2.709%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.95 |
Hot Take ↕ | Aug. 22, 2026, 1:59 a.m. EDT
The investment case for MannKind remains fractured despite the glowing analyst consensus. While the forward P/E looks attractive on paper, the company is burning cash with negative operating margins and a book value that has eroded significantly. The price action confirms this skepticism: the stock is down nearly 23% year-over-year, and the recent 14-day trend shows a distinct drift lower, failing to capitalize on the latest clinical progress news. The most critical signal here is the disconnect between the 'Strong Buy' analyst ratings and the reality of the balance sheet. With debt exceeding cash reserves and no dividend to cushion the blow, the stock relies entirely on future drug approvals to reverse fortunes. However, the options market tells a different story than Wall Street analysts; traders are aggressively buying puts, betting that the current price is a trap waiting to snap. This defensive positioning suggests that even the optimists are worried about a deeper fall before any recovery can begin. Until the company demonstrates sustained profitability or a clear path to cash flow generation, this remains a speculative hold with significant downside risk. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.067061 |
| MSTL | 0.136576 |
| AutoETS | 0.161352 |
| AutoARIMA | 0.161354 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.24 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.606 |
| Excess Kurtosis | -0.73 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 1.423 |
| Market Cap | 1,270,100,736 |
| Forward P/E | 30.98 |
| Beta | 1.10 |
| Profit Margins | -11.08% |
| Website | https://mannkindcorp.com |
As of Aug. 22, 2026, 1:59 a.m. EDT: Speculators are heavily positioning for downside protection rather than upside breakout. There is massive volume in out-of-the-money puts (especially the $3 strike) compared to calls, indicating a fear of further decline. Conversely, call volume is concentrated deep in-the-money at the $1 strike, suggesting a 'bag holder' strategy where investors are buying insurance against a drop below $1 rather than betting on a rally. The lack of significant open interest in OTM calls suggests the market does not expect a rapid recovery to $5+ anytime soon.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.31184667 |
| Address1 | 1 Casper Street |
| All Time High | 121.55 |
| All Time Low | 0.67 |
| Ask | 5.03 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 3,180,230 |
| Average Daily Volume3 Month | 4,710,468 |
| Average Volume | 4,710,468 |
| Average Volume10Days | 3,180,230 |
| Beta | 1.099 |
| Bid | 2.93 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | -0.217 |
| City | Danbury |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.95 |
| Current Ratio | 1.719 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.075 |
| Day Low | 3.93 |
| Display Name | MannKind |
| Dividend Date | 1,488,499,200 |
| Earnings Call Timestamp End | 1,785,960,000 |
| Earnings Call Timestamp Start | 1,785,960,000 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | 19,535,000 |
| Ebitda Margins | 0.049629997 |
| Enterprise To Ebitda | 81.535 |
| Enterprise To Revenue | 4.046 |
| Enterprise Value | 1,592,786,560 |
| Eps Current Year | 0.03 |
| Eps Forward | 0.1275 |
| Eps Trailing Twelve Months | -0.15 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.0316 |
| Fifty Day Average Change | -0.08159995 |
| Fifty Day Average Change Percent | -0.02024009 |
| Fifty Two Week Change Percent | -31.184668 |
| Fifty Two Week High | 6.51 |
| Fifty Two Week High Change | -2.5600002 |
| Fifty Two Week High Change Percent | -0.39324117 |
| Fifty Two Week Low | 2.23 |
| Fifty Two Week Low Change | 1.72 |
| Fifty Two Week Low Change Percent | 0.77130044 |
| Fifty Two Week Range | 2.23 - 6.51 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,091,021,400,000 |
| Float Shares | 297,527,982 |
| Forward Eps | 0.1275 |
| Forward P E | 30.980392 |
| Free Cashflow | 40,309,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 591 |
| Fullday Change | -0.11 |
| Fullday Change Percent | -2.70936 |
| Fullday Price | 3.95 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.75386 |
| Gross Profits | 296,742,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.014680001 |
| Held Percent Institutions | 0.57294 |
| Implied Shares Outstanding | 321,544,484 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.mannkindcorp.com/investors-mannkind.aspx |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,488,499,200 |
| Last Split Factor | 1:5 |
| Long Business Summary | MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. |
| Long Name | MannKind Corporation |
| Market | us_market |
| Market Cap | 1,270,100,736 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_9282918 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -43,614,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,305,470,605 |
| Number Of Analyst Opinions | 8 |
| Open | 4.06 |
| Operating Cashflow | -8,054,000 |
| Operating Margins | -0.00764 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 4.39 |
| Phone | 818 661 5000 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.95 |
| Post Market Time | 1,787,960,263 |
| Previous Close | 4.06 |
| Price Eps Current Year | 131.66667 |
| Price Hint | 4 |
| Price To Book | -18.202766 |
| Price To Sales Trailing12 Months | 3.2266443 |
| Profit Margins | -0.1108 |
| Quick Ratio | 1.287 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.11 |
| Regular Market Change Percent | -2.70936 |
| Regular Market Day High | 4.075 |
| Regular Market Day Low | 3.93 |
| Regular Market Day Range | 3.93 - 4.075 |
| Regular Market Open | 4.06 |
| Regular Market Previous Close | 4.06 |
| Regular Market Price | 3.95 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,984,111 |
| Return On Assets | 0.00794 |
| Revenue Growth | 0.429 |
| Revenue Per Share | 1.423 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 321,544,484 |
| Shares Percent Shares Out | 0.0889 |
| Shares Short | 28,582,134 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 28,190,841 |
| Short Name | MannKind Corporation |
| Short Percent Of Float | 0.090100005 |
| Short Ratio | 5.92 |
| Source Interval | 15 |
| State | CT |
| Symbol | MNKD |
| Target High Price | 13.0 |
| Target Low Price | 4.75 |
| Target Mean Price | 7.96875 |
| Target Median Price | 7.5 |
| Total Cash | 111,130,000 |
| Total Cash Per Share | 0.346 |
| Total Debt | 433,831,008 |
| Total Revenue | 393,628,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.15 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.1854 |
| Two Hundred Day Average Change | -0.23539996 |
| Two Hundred Day Average Change Percent | -0.05624312 |
| Type Disp | Equity |
| Volume | 1,984,111 |
| Website | https://mannkindcorp.com |
| Zip | 6,810 |